Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2029

Conditions
Lung Cancer Stage IIIMutation
Interventions
DRUG

Sunvozertinib

300 mg orally once a day, 28 days as one cycle.

DRUG

Crizotinib

300 mg orally once a day, 28 days as one cycle.

DRUG

Pralsetinib

400 mg orally once a day, 28 days as one cycle.

DRUG

Larotrectinib

100 mg orally twice daily, 28 days as one cycle.

DRUG

Savolitinib

600 mg or 400 mg (weight \<50 kg) orally once a day, 28 days as one cycle.

DRUG

Pyrotinib

400 mg orally once a day, 28 days as one cycle.

DRUG

Dabrafenib+Trametinib

Dabrafenib 150 mg orally twice daily, 28 days as one cycle. Trametinib 150 mg orally twice daily, 28 days as one cycle.

DRUG

Glecirasib

800 mg daily orally, 28 days as one cycle.

DRUG

Ensartinib

225 mg daily orally, 28 days as one cycle.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER